Aarti Pharmalabs Limited announced that its emissions targets were approved by the Science Based Targets initiative (SBTi).

This approval encompasses all three emission scopes, making Aarti Pharmalabs Limited the 6th pharmaceutical company in India to achieve the comprehensive validation.

“We are excited to embark on this next phase of our sustainability journey and are confident that by working together, we can make a meaningful difference,” said Hetal Gogri Gala, vice chairperson and managing director at Aarti Pharmalabs Limited, in a statement.

Aarti Pharmalabs Limited commits to reach net-zero GHG emissions across the value chain by FY2050. The company commits to lower absolute Scope 1 and 2 GHG emissions 37.8% by FY2030 from a FY2024 base year as well as reduce absolute Scope 3 GHG emissions 22.5% within the same timeframe.

The company commits to reduce absolute Scope 1 and 2 GHG emissions 90% by FY2050 from a FY2024 base year and reduce absolute Scope 3 GHG emissions 90% within the same timeframe.

Aarti’s target boundary includes land-related emissions and removals from bioenergy feedstocks. The company plans to focus on developing innovation through the adoption of low-carbon technologies, further optimizing its operational efficiency, and fostering strong collaborations with its partners throughout the value chain to achieve its targets.